ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

Hans Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy S Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa Lapteva & 25 others Adeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton J. Rabelink, Andreas Radbruch, Andrew Rees, Mary M. Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J. Schall, Catherine Meyer-Schwesinger, Sanjib Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, Ming Hui Zhao

Research output: Contribution to journalArticleResearchpeer-review

Abstract

To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

Original languageEnglish
Pages (from-to)327-339
Number of pages13
JournalKidney International Reports
Volume1
Issue number4
DOIs
Publication statusPublished - 2016

Keywords

  • autoimmunity
  • inflammation
  • lupus
  • rejection
  • stem cells
  • vasculitis

Cite this

Anders, H. J., Rovin, B., Jayne, D., Brunetta, P., Coppo, R., Davidson, A., ... Zhao, M. H. (2016). ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. Kidney International Reports, 1(4), 327-339. https://doi.org/10.1016/j.ekir.2016.06.009
Anders, Hans Joachim ; Rovin, Brad ; Jayne, David ; Brunetta, Paul ; Coppo, Rosanna ; Davidson, Anne ; Devarapu, Satish Kumar ; de Zeeuw, Dick ; Duffield, Jeremy S ; Eulberg, Dirk ; Fierro, Alberto ; Floege, Jürgen ; Frese, Steffen ; Guillevin, Loïc ; Holdsworth, Stephen ; Hughes, Jeremy ; Kettritz, Ralph ; Kluger, Malte ; Krebs, Christian ; Lapteva, Larissa ; Levin, Adeera ; Li, Jinhua ; Lightstone, Liz ; Mack, Matthias ; Mansouri, Ladan ; McAdoo, Stephen ; McKinney, Eoin ; Panzer, Ulf ; Parikh, Samir ; Pusey, Charles ; Putterman, Chaim ; Rabelink, Ton J. ; Radbruch, Andreas ; Rees, Andrew ; Reilly, Mary M. ; Reinders, Marlies ; Remuzzi, Giuseppe ; Ruggenenti, Piero ; Sacks, Steven ; Schall, Thomas J. ; Meyer-Schwesinger, Catherine ; Sharma, Sanjib Kumar ; Suzuki, Yusuke ; Tomas, Nicola M. ; Zhao, Ming Hui. / ISN Nexus 2016 Symposia : Translational Immunology in Kidney Disease—The Berlin Roadmap. In: Kidney International Reports. 2016 ; Vol. 1, No. 4. pp. 327-339.
@article{5f6925618d9a434eb80ccb05a0daa73c,
title = "ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap",
abstract = "To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.",
keywords = "autoimmunity, inflammation, lupus, rejection, stem cells, vasculitis",
author = "Anders, {Hans Joachim} and Brad Rovin and David Jayne and Paul Brunetta and Rosanna Coppo and Anne Davidson and Devarapu, {Satish Kumar} and {de Zeeuw}, Dick and Duffield, {Jeremy S} and Dirk Eulberg and Alberto Fierro and J{\"u}rgen Floege and Steffen Frese and Lo{\"i}c Guillevin and Stephen Holdsworth and Jeremy Hughes and Ralph Kettritz and Malte Kluger and Christian Krebs and Larissa Lapteva and Adeera Levin and Jinhua Li and Liz Lightstone and Matthias Mack and Ladan Mansouri and Stephen McAdoo and Eoin McKinney and Ulf Panzer and Samir Parikh and Charles Pusey and Chaim Putterman and Rabelink, {Ton J.} and Andreas Radbruch and Andrew Rees and Reilly, {Mary M.} and Marlies Reinders and Giuseppe Remuzzi and Piero Ruggenenti and Steven Sacks and Schall, {Thomas J.} and Catherine Meyer-Schwesinger and Sharma, {Sanjib Kumar} and Yusuke Suzuki and Tomas, {Nicola M.} and Zhao, {Ming Hui}",
year = "2016",
doi = "10.1016/j.ekir.2016.06.009",
language = "English",
volume = "1",
pages = "327--339",
journal = "Kidney International Reports",
issn = "2468-0249",
publisher = "Elsevier",
number = "4",

}

Anders, HJ, Rovin, B, Jayne, D, Brunetta, P, Coppo, R, Davidson, A, Devarapu, SK, de Zeeuw, D, Duffield, JS, Eulberg, D, Fierro, A, Floege, J, Frese, S, Guillevin, L, Holdsworth, S, Hughes, J, Kettritz, R, Kluger, M, Krebs, C, Lapteva, L, Levin, A, Li, J, Lightstone, L, Mack, M, Mansouri, L, McAdoo, S, McKinney, E, Panzer, U, Parikh, S, Pusey, C, Putterman, C, Rabelink, TJ, Radbruch, A, Rees, A, Reilly, MM, Reinders, M, Remuzzi, G, Ruggenenti, P, Sacks, S, Schall, TJ, Meyer-Schwesinger, C, Sharma, SK, Suzuki, Y, Tomas, NM & Zhao, MH 2016, 'ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap' Kidney International Reports, vol. 1, no. 4, pp. 327-339. https://doi.org/10.1016/j.ekir.2016.06.009

ISN Nexus 2016 Symposia : Translational Immunology in Kidney Disease—The Berlin Roadmap. / Anders, Hans Joachim; Rovin, Brad; Jayne, David; Brunetta, Paul; Coppo, Rosanna; Davidson, Anne; Devarapu, Satish Kumar; de Zeeuw, Dick; Duffield, Jeremy S; Eulberg, Dirk; Fierro, Alberto; Floege, Jürgen; Frese, Steffen; Guillevin, Loïc; Holdsworth, Stephen; Hughes, Jeremy; Kettritz, Ralph; Kluger, Malte; Krebs, Christian; Lapteva, Larissa; Levin, Adeera; Li, Jinhua; Lightstone, Liz; Mack, Matthias; Mansouri, Ladan; McAdoo, Stephen; McKinney, Eoin; Panzer, Ulf; Parikh, Samir; Pusey, Charles; Putterman, Chaim; Rabelink, Ton J.; Radbruch, Andreas; Rees, Andrew; Reilly, Mary M.; Reinders, Marlies; Remuzzi, Giuseppe; Ruggenenti, Piero; Sacks, Steven; Schall, Thomas J.; Meyer-Schwesinger, Catherine; Sharma, Sanjib Kumar; Suzuki, Yusuke; Tomas, Nicola M.; Zhao, Ming Hui.

In: Kidney International Reports, Vol. 1, No. 4, 2016, p. 327-339.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - ISN Nexus 2016 Symposia

T2 - Translational Immunology in Kidney Disease—The Berlin Roadmap

AU - Anders, Hans Joachim

AU - Rovin, Brad

AU - Jayne, David

AU - Brunetta, Paul

AU - Coppo, Rosanna

AU - Davidson, Anne

AU - Devarapu, Satish Kumar

AU - de Zeeuw, Dick

AU - Duffield, Jeremy S

AU - Eulberg, Dirk

AU - Fierro, Alberto

AU - Floege, Jürgen

AU - Frese, Steffen

AU - Guillevin, Loïc

AU - Holdsworth, Stephen

AU - Hughes, Jeremy

AU - Kettritz, Ralph

AU - Kluger, Malte

AU - Krebs, Christian

AU - Lapteva, Larissa

AU - Levin, Adeera

AU - Li, Jinhua

AU - Lightstone, Liz

AU - Mack, Matthias

AU - Mansouri, Ladan

AU - McAdoo, Stephen

AU - McKinney, Eoin

AU - Panzer, Ulf

AU - Parikh, Samir

AU - Pusey, Charles

AU - Putterman, Chaim

AU - Rabelink, Ton J.

AU - Radbruch, Andreas

AU - Rees, Andrew

AU - Reilly, Mary M.

AU - Reinders, Marlies

AU - Remuzzi, Giuseppe

AU - Ruggenenti, Piero

AU - Sacks, Steven

AU - Schall, Thomas J.

AU - Meyer-Schwesinger, Catherine

AU - Sharma, Sanjib Kumar

AU - Suzuki, Yusuke

AU - Tomas, Nicola M.

AU - Zhao, Ming Hui

PY - 2016

Y1 - 2016

N2 - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

AB - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

KW - autoimmunity

KW - inflammation

KW - lupus

KW - rejection

KW - stem cells

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84995563999&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2016.06.009

DO - 10.1016/j.ekir.2016.06.009

M3 - Article

VL - 1

SP - 327

EP - 339

JO - Kidney International Reports

JF - Kidney International Reports

SN - 2468-0249

IS - 4

ER -